Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334388 | 0.92 | ALDH1A1 (0.54) | LTA4HKCNH2KCNA5MCHR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2158155 | 0.91 | ALDH1A1 (0.53) | LTA4HKCNH2KCNA5MCHR1ALDH1A1 | |
| SCHEMBL2158179 | 0.90 | KCNH2 (0.64) | LTA4HKCNH2KCNA5 | |
| SCHEMBL2157439 | 0.87 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL2157359 | 0.86 | KCNH2 (0.61) | LTA4HKCNH2KCNA5ALDH1A1SLC6A4 | |
| SCHEMBL2158181 | 0.85 | DRD3 (0.56) | LTA4HKCNA5MCHR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL5131275 | 0.84 | DRD3 (0.55) | KCNA5MCHR1SLC6A3LMNA | |
| SCHEMBL7030939 | 0.84 | LTA4H (0.57) | LTA4HKCNH2MCHR1ALDH1A1USP2 | |
| SCHEMBL2157291 | 0.84 | SIGMAR1 (0.69) | LTA4HKCNH2ALDH1A1USP2HPGD | |
| SCHEMBL1334161 | 0.83 | KCNH2 (0.66) | LTA4HKCNH2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101511187-B | Piperidine and piperazine derivatives | MS SCIENCE CORP | 2012-07-04 | — | — | CN | disclosed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-1978959-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-09 | — | — | EP | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-1976525-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | LTA4H 2934/4885KCNH2 332/4885KCNA5 273/4885 |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | SIGMAR1, OPRM1, OPRD1 | LTA4H 3616/4885KCNH2 360/4885KCNA5 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.